CLK3-mediated phosphorylation of USP13 at Tyr708 promotes cholangiocarcinoma progression by activating c-Myc-induced purine synthesis, providing a new and viable therapeutic target for treating cholangiocarcinoma associated with CLK3 mutations [33]. The gene discussed is CLK3; the disease is cholangiocarcinoma.